2D MXene-Based Mesoporous Silica Nanoplatform for Autophagy Inhibition and Enhanced Photothermal Therapy of Hepatoblastoma.

Can Huang, Yangyang Jiao, Shayi Jiang, Xuelian Liao, Jingwei Yang

Abstract read

In one paragraph

Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Can HuangDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China.

Yangyang JiaoDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China.

Shayi JiangDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China.

Xuelian LiaoDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China.

Jingwei YangDepartment of Hematology and Oncology, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200062, China.ORCID 0009-0008-7067-4402

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatoblastoma (HB) has a subtle onset and poor prognosis in high-risk group patients. Due to the adverse reactions and drug resistance associated with traditional systemic chemotherapy, there is an urgent need for new treatment strategies. Photothermal therapy (PTT) has been proposed as an advanced, patient-centered approach for cancer treatment. However, the safety concerns regarding traditional photothermal agents and the existence of intracellular self-protective autophagy mechanisms have hindered the clinical application and efficacy of PTT. This paper reports the development of a two-dimensional (2D) MXene-based composite nanoplatform for efficient synergistic autophagy inhibition and PTT for HB. Here, by directly coating a mesoporous silica layer on the surface of 2D Nb

Indexed as

Antineoplastic AgentsAutophagyBiocompatible MaterialsHepatoblastomaLiver NeoplasmsNanoparticlesPhotothermal TherapySilicon DioxideAnimalsCell ProliferationCell SurvivalChloroquineDrug Screening Assays, AntitumorHumansMaterials TestingMiceAntineoplastic AgentsBiocompatible MaterialsChloroquineMXeneNitritesSilicon DioxideTransition Elementsautophagy inhibitionchildrenhepatoblastomamesoporous silicaNb2C MXenephotothermal therapy

Identifiers

PMID41670240

DOI10.1021/acsabm.5c02406

PMCPMC12958339

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.